pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,994 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1870Endpoints1449Fierce Biotech766BioSpace758BioPharma Dive548raps249onclive165fda recalls120
therapy area
allOncology12934Rare Disease3340Immunology3024Cardiology2859Hematology2298Pulmonology2255Vaccines
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 1d agoDealNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 1d agoDealNeutral↗ source
← prev
page 2 of 200
next →
fda medwatch115
globenewswire health73
fda press62
1854
Psychiatry & CNS1230
Ophthalmology1134
Endocrinology & Metabolism807
Pain791
Nephrology786
  • Biogen's low-dose tau drug shows greater slowing of Alzheimer’s progression after two years
    Biogen reported new data on its experimental tau-reducing therapy diranersen, showing that the lowest dose continued to slow Alzheimer’s disease progression after nearly two years of treatment. Th…
    Endpoints · 1d agoPositive readoutPositive↗ source
  • White House withdraws Trump nominee Heidi Overton from FDA commissioner consideration amid Senate doubts
    The White House announced it has pulled Heidi Overton, the Trump administration’s nominee to serve as commissioner of the Food and Drug Administration. Overton’s nomination had been moving through…
    Endpoints · 1d agoRegulatoryNegative↗ source
  • Epic Systems pledges broader AI access to its EHR data and defends its competitive practices at HLTH conference
    Epic Systems executives used a panel at the HLTH conference to respond to a STAT investigation that accused the company of limiting data access for rival developers. The company said it will make…
    STAT · 14h agoRegulatoryNeutral↗ source
  • Experts warn of safety risks as FDA targets compounded GLP-1 weight-loss drugs sold by telehealth firms
    At the HLTH conference, experts highlighted growing concerns about telehealth companies that sell compounded GLP-1 weight-loss medications. These firms create custom formulations and ship them dir…
    BioPharma Dive · 18h agoRegulatoryNegative↗ source
  • Novo accelerates consumer focus with Wegovy pill launch and upcoming CagriSema, as marketing chief Ed Cinca returns
    Novo is intensifying its consumer‑focused strategy, highlighted by the Wegovy oral pill and the forthcoming CagriSema product. The effort coincides with the return of senior vice president of mark…
    Endpoints · 19h agoPositive↗ source
  • Eli Lilly's Alzheimer's drug mevidalen fails Phase 2 trial
    Eli Lilly conducted a Phase 2 trial of mevidalen, a dopamine-modulating compound, in patients with mild to moderate Alzheimer's disease. The study did not meet its primary efficacy endpoints, indi…
    Endpoints · 21h agoNegative readoutNegative↗ source
  • Trump administration withdraws Heidi Overton’s FDA nomination amid Senate support concerns
    The Trump administration has pulled the nomination of Heidi Overton to become the U.S. Food and Drug Administration commissioner, saying she lacked sufficient backing to win Senate confirmation. T…
    STAT · 23h agoRegulatoryNeutral↗ source
  • Debate Over Medical School Structure Emerges as U.S. Loses Measles Elimination Status
    A discussion is unfolding about whether the traditional four‑year medical school model should be broken into separate components. The idea was voiced by a medical student who asked if every part of…
    STAT · 1d agoNegative↗ source
  • Loss of Senate Appropriations Chair Susan Collins could weaken scientists’ fight against new research oversight rule
    Senator Susan Collins, the Republican chair of the Senate Appropriations Committee, was defeated in her re‑election, ending her role as the most prominent GOP ally for science advocates. Scientist…
    STAT · 1d agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate opposition
    The White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…
    BioSpace · 1d agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton's nomination to lead the FDA amid Senate Republican concerns
    The White House announced it is withdrawing its nominee, Heidi Overton, for FDA commissioner. Overton, a preventive care physician who previously served in the Trump administration, faced resistan…
    STAT · 1d agoRegulatoryNegative↗ source
  • Heidi Overton’s FDA nomination stalls as Senate HELP Committee vote fails
    Heidi Overton, the Trump administration’s pick for FDA commissioner, faced a decisive vote before the Senate HELP Committee less than a day after her testimony. The committee’s deliberations were…
    Endpoints · 15h agoRegulatoryNegative↗ source
  • STAT+: Influential preventive services panel to meet for first time in more than a year
    A task force, meeting after a long delay, will discuss coverage of treatments for cervical cancer, perinatal depression, and alcohol use.
    STAT · 16h agoRegulatoryNeutral↗ source
  • AI scribe market sees early winners and losers as HLTH conference highlights industry shifts
    The latest AI Prognosis newsletter from STAT examines how the artificial-intelligence scribe sector is beginning to separate into clear frontrunners and laggards. At the HLTH conference, a Startup…
    STAT · 18h agoNeutral↗ source
  • Hims & Hers adds peptide and longevity treatments to its telehealth lineup
    Hims & Hers announced on Wednesday that it is now offering a range of peptide-based products and other treatments marketed for longevity and wellness. The new portfolio expands the company's teleh…
    Endpoints · 18h agoPositive↗ source
  • Jefferies Global Healthcare Conference Highlights AI, PI3Kα and Protein Degrader Strategies
    Long queues formed outside the Waldorf Hilton in London as attendees arrived for the 17th Jefferies Global Healthcare Conference. The event gathered investors, executives and scientists eager to he…
    Endpoints · 22h agoNeutral↗ source
  • 8 companies hiring in North Carolina now
    Looking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you.
    BioSpace · 23h agoRegulatoryNeutral↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 1d agoNeutral↗ source
  • Senate health panel blocks Trump pick for NSF over science integrity concerns
    The Senate health committee rejected the nomination of Jim O’Neill to lead the National Science Foundation after Chair Bill Cassidy voiced doubts about his commitment to scientific integrity. Cass…
    STAT · 22h agoRegulatoryNegative↗ source
  • NIH to relocate its final research chimpanzees to sanctuary in Texas next year
    The National Institutes of Health announced that the last group of government‑owned chimpanzees still housed in a laboratory will be moved to a sanctuary early next year. The animals, about three d…
    STAT · 17h agoPositive↗ source
  • Opinion calls for impeachment of Health Secretary Robert F. Kennedy Jr. over anti‑vaccine stance
    Professor Paul Knoepfler, a cell‑biology faculty member at UC Davis, argues that the post‑midterm political climate creates a window to remove Health and Human Services Secretary Robert F. Kennedy…
    STAT · 1d agoNegative↗ source
  • Opinion argues that traditional four-year medical schools may be outdated for pre-clerkship training
    Alex Serafini, a fourth‑year medical student at Icahn School of Medicine, contributes to a new First Opinion series that questions the structure of modern medical education. He notes that over the…
    STAT · 1d agoNeutral↗ source
  • Why comparing every new employer to your last one can hurt your influence
    Executive coach Angela Justice advises professionals not to treat their former workplace as the standard for every new job. She says the habit can cloud judgment and reduce a person's influence. W…
    BioSpace · 1d agoNeutral↗ source